Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Technology
1.1.2. Application
1.1.3. Method
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Technology outlook
2.2.2. Application outlook
2.2.3. Method outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. ADME Toxicology Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. ADME Toxicology Testing Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. ADME Toxicology Testing: Technology Estimates & Trend Analysis
4.1. ADME Toxicology Testing Market: Key Takeaways
4.2. ADME Toxicology Testing Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Cell Culture
4.3.1. Cell Culture market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. High Throughput
4.4.1. High throughput market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Molecular Imaging
4.5.1. Molecular imaging market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. OMICS Technology
4.6.1. OMICS technology market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. ADME Toxicology Testing Market: Application Estimates & Trend Analysis
5.1. ADME Toxicology Testing Market: Key Takeaways
5.2. ADME Toxicology Testing Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Systemic Toxicity
5.3.1. Systemic toxicity market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Renal Toxicity
5.4.1. Renal toxicity market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Hepatotoxicity
5.5.1. Hepatotoxicity market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Neurotoxicity
5.6.1. Neurotoxicity market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Other Toxicities
5.7.1. Other toxicities market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. ADME Toxicology Testing Market: Method Estimates & Trend Analysis
6.1. ADME Toxicology Testing Market: Key Takeaways
6.2. ADME Toxicology Testing Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Cellular Assay
6.3.1. Cellular assay market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Biochemical Assay
6.4.1. Biochemical assay market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. In-Silica
6.5.1. In-silica market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Ex-vivo
6.6.1. Ex-vivo market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. ADME Toxicology Testing Market: Regional Estimates & Trend Analysis
7.1. Regional Outlook
7.2. ADME Toxicology Testing Market by Region: Key Takeaway
7.3. North America
7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.3.2. U.S.
7.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.3.3. Canada
7.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.2. Germany
7.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.3. France
7.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.4. Italy
7.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.5. Spain
7.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.6. Sweden
7.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.7. Norway
7.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.8. Denmark
7.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.2. China
7.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.3. India
7.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.4. Australia
7.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.5. Thailand
7.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.6. South Korea
7.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6.2. Mexico
7.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6.3. Argentina
7.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.3. UAE
7.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.4. Kuwait
7.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Market Participant Categorization
8.2.1. Thermo Fisher Scientific Inc.
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Promega Corporation
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Agilent Technologies, Inc.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Curia Global, Inc.
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Dassault Systèmes
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Beckman Coulter, Inc., (Danaher)
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Catalent, Inc
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Charles River Laboratories
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Labcorp Drug Development
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Eurofins Scientific
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
8.2.11. GE HealthCare
8.2.11.1. Company overview
8.2.11.2. Financial performance
8.2.11.3. Product benchmarking
8.2.11.4. Strategic initiatives
8.2.12. Miltenyi Biotec
8.2.12.1. Company overview
8.2.12.2. Financial performance
8.2.12.3. Product benchmarking
8.2.12.4. Strategic initiatives
8.2.13. IQVIA Inc
8.2.13.1. Company overview
8.2.13.2. Financial performance
8.2.13.3. Product benchmarking
8.2.13.4. Strategic initiatives